237P - Personalized peptide vaccine induced adoptive immunocyte transfer combined chemotherapy and radiation improved the survival of advanced pancreatic...

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Poster lunch
Topics Cytotoxic agents
Immunotherapy
Pancreatic Cancer
Gastrointestinal Cancers
Personalised/Precision medicine
Surgical oncology
Basic Principles in the Management and Treatment (of cancer)
Therapy
Biological therapy
Radiation oncology
Presenter Qin Liu
Citation Annals of Oncology (2017) 28 (suppl_10): x57-x76. 10.1093/annonc/mdx660
Authors Q. Liu1, Z. Zou1, W. Kong2, F. Chen1, F. Meng1, B. Liu1
  • 1The Comprehensive Cancer Centre Of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, 210008 - Nanjing/CN
  • 2The Comprehensive Cancer Center, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, 210008 - Nanjing/CN

Abstract

Background

Pancreatic cancer (PC) is one of the most aggressive and death-relating malignancy. Gemcitabine (GEM) is the key agent in the first-line standard regimen for advanced PC, which is mostly diagnosed at advanced stage and unsuitable for curative resection. The objective responsive rate (ORR) and medium progression free survival (PFS) of various GEM-based regimens are still unsatisfied. Therefore, development of new therapeutic modalities, including immunotherapy, is needed. This study is to investigate the efficacy, safety and clinical beneficial of combination personalized immunotherapy with GEM and radiotherapy in locally advanced and metastatic PC patients.

Methods

Three locally advanced unresectable and seven metastatic PC patients received at least two cycles of GEM (1000mg/m2 on day 1 and day 6), radiotherapy combing with personalized peptide vaccine induced DC vaccination on day 7 and cytotoxic T lymphocyte transfer from day 12 to 15 (repeated every 21 days). The locally advanced unresectable PC patients received stereotactic body radiotherapy (SBRT) with a total amount of 50-66Gy during the first cycle. For metastatic patients, their partial lesions received a low dose radiation (0.5Gy bid*2 days) on day 10 and 11 in each cycle.

Results

Two cases were observed with partial remission (PR), five with stable disease (sd), and three with progressive disease (PD). The disease control rate (DCR) was 70%. Median progression free survival (PFS) was 6.4 months. After the first treatment cycle, the total effectiveness for pain easement and increasing appetite are 100% (8/8) and 66.7%, respectively. Haematotoxicities with a 40% incidence rate were the most common adverse drug reactions. Two patients had grade 1 to 2 neutropenia, two with grade 3 to 4 thrombocytopenia. Three patients suffered grade 1 to 2 gemcitabine-induced skin rash. No treatment-related mortality occurred.

Conclusions

Personalized adoptive immunocyte transfer combined chemoradiotherapy demonstrated an acceptable response and safety in advanced pancreatic cancer patients.

Clinical trial identification

Legal entity responsible for the study

The Comprehensive Cancer Centre of Drum Tower Hospital

Funding

None

Disclosure

All authors have declared no conflicts of interest.